vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Purple Innovation, Inc. (PRPL). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $140.7M, roughly 1.8× Purple Innovation, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -2.3%, a 13.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 9.1%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-7.8M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 8.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
ANIP vs PRPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $140.7M |
| Net Profit | $27.5M | $-3.2M |
| Gross Margin | — | 41.9% |
| Operating Margin | 14.1% | -1.6% |
| Net Margin | 11.1% | -2.3% |
| Revenue YoY | 29.6% | 9.1% |
| Net Profit YoY | 367.5% | 62.1% |
| EPS (diluted) | $1.14 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $140.7M | ||
| Q3 25 | $227.8M | $118.8M | ||
| Q2 25 | $211.4M | $105.1M | ||
| Q1 25 | $197.1M | $104.2M | ||
| Q4 24 | $190.6M | $129.0M | ||
| Q3 24 | $148.3M | $118.6M | ||
| Q2 24 | $138.0M | $120.3M | ||
| Q1 24 | $137.4M | $120.0M |
| Q4 25 | $27.5M | $-3.2M | ||
| Q3 25 | $26.6M | $-11.7M | ||
| Q2 25 | $8.5M | $-17.3M | ||
| Q1 25 | $15.7M | $-19.1M | ||
| Q4 24 | $-10.3M | $-8.5M | ||
| Q3 24 | $-24.2M | $-39.2M | ||
| Q2 24 | $-2.3M | $27.0K | ||
| Q1 24 | $18.2M | $-50.2M |
| Q4 25 | — | 41.9% | ||
| Q3 25 | — | 42.8% | ||
| Q2 25 | — | 35.9% | ||
| Q1 25 | — | 39.4% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | 34.8% |
| Q4 25 | 14.1% | -1.6% | ||
| Q3 25 | 15.9% | -10.2% | ||
| Q2 25 | 6.6% | -13.5% | ||
| Q1 25 | 13.3% | -13.9% | ||
| Q4 24 | -2.3% | -6.0% | ||
| Q3 24 | -13.8% | -39.5% | ||
| Q2 24 | 3.7% | -12.1% | ||
| Q1 24 | 14.8% | -19.3% |
| Q4 25 | 11.1% | -2.3% | ||
| Q3 25 | 11.7% | -9.9% | ||
| Q2 25 | 4.0% | -16.5% | ||
| Q1 25 | 8.0% | -18.4% | ||
| Q4 24 | -5.4% | -6.6% | ||
| Q3 24 | -16.3% | -33.1% | ||
| Q2 24 | -1.7% | 0.0% | ||
| Q1 24 | 13.2% | -41.8% |
| Q4 25 | $1.14 | $0.03 | ||
| Q3 25 | $1.13 | $0.11 | ||
| Q2 25 | $0.36 | $0.16 | ||
| Q1 25 | $0.69 | $0.18 | ||
| Q4 24 | $-0.45 | $0.08 | ||
| Q3 24 | $-1.27 | $0.36 | ||
| Q2 24 | $-0.14 | $0.00 | ||
| Q1 24 | $0.82 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $24.3M |
| Total DebtLower is stronger | — | $126.7M |
| Stockholders' EquityBook value | $540.7M | $-29.7M |
| Total Assets | $1.4B | $296.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $24.3M | ||
| Q3 25 | $262.6M | $32.4M | ||
| Q2 25 | $217.8M | $34.2M | ||
| Q1 25 | $149.8M | $21.6M | ||
| Q4 24 | $144.9M | $29.0M | ||
| Q3 24 | $145.0M | $23.4M | ||
| Q2 24 | $240.1M | $23.4M | ||
| Q1 24 | $228.6M | $34.5M |
| Q4 25 | — | $126.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $-29.7M | ||
| Q3 25 | $505.8M | $-26.9M | ||
| Q2 25 | $436.8M | $-15.6M | ||
| Q1 25 | $418.6M | $1.3M | ||
| Q4 24 | $403.7M | $20.2M | ||
| Q3 24 | $405.9M | $28.0M | ||
| Q2 24 | $455.8M | $66.4M | ||
| Q1 24 | $452.0M | $65.5M |
| Q4 25 | $1.4B | $296.3M | ||
| Q3 25 | $1.4B | $302.1M | ||
| Q2 25 | $1.3B | $303.8M | ||
| Q1 25 | $1.3B | $293.8M | ||
| Q4 24 | $1.3B | $307.8M | ||
| Q3 24 | $1.3B | $309.3M | ||
| Q2 24 | $920.8M | $362.1M | ||
| Q1 24 | $914.5M | $382.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-5.8M |
| Free Cash FlowOCF − Capex | $29.1M | $-7.8M |
| FCF MarginFCF / Revenue | 11.8% | -5.5% |
| Capex IntensityCapex / Revenue | 0.5% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-5.8M | ||
| Q3 25 | $44.1M | $-968.0K | ||
| Q2 25 | $75.8M | $-4.0M | ||
| Q1 25 | $35.0M | $-23.1M | ||
| Q4 24 | $15.9M | $6.8M | ||
| Q3 24 | $12.5M | $1.1M | ||
| Q2 24 | $17.4M | $-8.9M | ||
| Q1 24 | $18.3M | $-16.8M |
| Q4 25 | $29.1M | $-7.8M | ||
| Q3 25 | $38.0M | $-1.8M | ||
| Q2 25 | $71.8M | $-7.0M | ||
| Q1 25 | $32.5M | $-25.3M | ||
| Q4 24 | $13.5M | $5.7M | ||
| Q3 24 | $7.7M | $101.0K | ||
| Q2 24 | $13.0M | $-11.0M | ||
| Q1 24 | $13.7M | $-19.9M |
| Q4 25 | 11.8% | -5.5% | ||
| Q3 25 | 16.7% | -1.5% | ||
| Q2 25 | 34.0% | -6.6% | ||
| Q1 25 | 16.5% | -24.3% | ||
| Q4 24 | 7.1% | 4.4% | ||
| Q3 24 | 5.2% | 0.1% | ||
| Q2 24 | 9.4% | -9.2% | ||
| Q1 24 | 10.0% | -16.5% |
| Q4 25 | 0.5% | 1.4% | ||
| Q3 25 | 2.7% | 0.7% | ||
| Q2 25 | 1.9% | 2.8% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 1.3% | 0.8% | ||
| Q3 24 | 3.2% | 0.9% | ||
| Q2 24 | 3.2% | 1.7% | ||
| Q1 24 | 3.3% | 2.5% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -330.22× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
